JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $213
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Anupam Rama maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and lowers the price target from $217 to $213.

June 23, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Sarepta Therapeutics and lowers the price target from $217 to $213.
The news of JP Morgan maintaining an Overweight rating on Sarepta Therapeutics and lowering the price target from $217 to $213 indicates that the analyst still has a positive outlook on the company, but with a slightly reduced target. This may not have a significant short-term impact on the stock price, as the change in target is relatively small.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100